Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CPIX Stock Forecast 2026-2027
$3.04
Current Price
$45.47M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CPIX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CPIX Price Momentum
-13.1%
1 Week Change
-21.6%
1 Month Change
-44.3%
1 Year Change
-23.6%
Year-to-Date Change
-51.5%
From 52W High of $6.27
+64.3%
From 52W Low of $1.85
📊 TOP ANALYST CALLS
Did CPIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cumberland Pharmaceuticals is one of their latest high-conviction picks.
Latest CPIX Stock Price Targets & Analyst Predictions
CPIX has shown a year-to-date change of -23.6% and a 1-year change of -44.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CPIX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CPIX Analyst Ratings
0
Buy
1
Hold
0
Sell
CPIX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.04
Latest CPIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CPIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2019 | B. Riley Securities | Andrew D'Silva | Buy | Maintains | $9.75 |
| Dec 3, 2019 | B. Riley | Buy | Maintains | $N/A | |
| Nov 18, 2019 | B. Riley Securities | Buy | Maintains | $9.00 | |
| Nov 18, 2019 | B. Riley FBR | Buy | Maintains | $N/A | |
| Aug 17, 2018 | B. Riley Securities | Andrew D'Silva | Buy | Maintains | $8.75 |
| Aug 17, 2018 | B. Riley FBR | Buy | Maintains | $N/A | |
| May 5, 2018 | B. Riley FBR | Buy | Initiates | $N/A | |
| Apr 17, 2018 | B. Riley Securities | Buy | Initiates | $N/A | |
| Apr 17, 2018 | B. Riley FBR | Buy | Initiates | $N/A | |
| Apr 10, 2013 | UBS | Neutral | Maintains | $5.50 | |
| Nov 12, 2012 | UBS | Neutral | Maintains | $5.00 | |
| Nov 9, 2012 | Wells Fargo | Market Perform | Downgrade | $N/A |
Cumberland Pharmaceuticals Inc. (CPIX) Competitors
The following stocks are similar to Cumberland Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CPIX
Cumberland Pharmaceuticals
mkt cap
52.36M
Cumberland Pharmaceuticals Inc. (CPIX) Financial Data
Cumberland Pharmaceuticals Inc. has a market capitalization of $45.47M with a P/E ratio of -6.6x. The company generates $44.52M in trailing twelve-month revenue with a -6.4% profit margin.
Revenue growth is +31.1% quarter-over-quarter, while maintaining an operating margin of -10.0% and return on equity of -12.2%.
Valuation Metrics
Market Cap
$45.47M
Enterprise Value
$44.47M
P/E Ratio
-6.6x
PEG Ratio
0.2x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+31.1%
Gross Margin
N/A
Operating Margin
-10.0%
Net Margin
-6.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+25.2%
Current Ratio
1.0x
Debt/Equity
41.5x
ROE
-12.2%
ROA
-2.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cumberland Pharmaceuticals Inc. (CPIX) Business Model
About Cumberland Pharmaceuticals Inc.
What They Do
Develops innovative prescription products for healthcare.
Business Model
Cumberland Pharmaceuticals generates revenue by developing and commercializing niche-market prescription products that cater to specific medical needs in hospital acute care, gastroenterology, and oncology. The company employs a direct salesforce and partners with healthcare providers and distributors to maximize product availability across the U.S.
Additional Information
Founded in 1999 and headquartered in Nashville, Tennessee, Cumberland Pharmaceuticals is dedicated to improving patient care by addressing significant medical needs and expanding therapeutic options, thereby playing a critical role in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
91
CEO
Mr. A. J. Kazimi MBA
Country
United States
IPO Year
2009
Website
www.cumberlandpharma.comCumberland Pharmaceuticals Inc. (CPIX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales
CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.
Mar 10, 2026
By Zacks Equity Research
Microcap Article
Latest News
Quick Summary
CPIX reported a 31% increase in Q4 revenues, with narrowed losses year over year, driven by sales of Vibativ, Sancuso, and the new product Talicia.
Why It Matters
CPIX's revenue growth and reduced losses indicate strong performance and potential for profitability, making it an attractive option for investors looking for growth opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript
10 days ago
Quick Summary
Cumberland Pharmaceuticals Inc. (CPIX) held its Q4 2025 earnings call, discussing financial performance and future outlook. Further details can be found in the prepared remarks transcript.
Why It Matters
Cumberland Pharmaceuticals' Q4 earnings reveal financial performance and future guidance, influencing stock valuation and investor sentiment on growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cumberland Pharmaceuticals reported Q4 2025 net revenues of $13.7 million, a 31% increase year-over-year, highlighting progress in financial, international, portfolio, and clinical areas.
Why It Matters
Cumberland Pharmaceuticals' 31% revenue growth signals strong demand for its products, indicating potential for continued financial performance and investment opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has launched a national sales promotion for Talicia®, targeting rare disease treatments.
Why It Matters
Cumberland Pharmaceuticals' launch of a national sales promotion for Talicia® signals potential revenue growth, which could positively impact stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) will release its 2025 financial results and company update on March 3, 2026, after market close.
Why It Matters
Cumberland Pharmaceuticals' upcoming financial results can impact stock performance, revealing insights into revenue growth, profitability, and future outlook, influencing investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Talicia Holdings Inc. has launched the full sales and operational rollout of Talicia, a leading H. pylori therapy, under a joint agreement with Cumberland to enhance market penetration.
Why It Matters
The launch of Talicia signifies a strategic growth opportunity for RedHill and Cumberland, potentially boosting revenues in the competitive H. pylori treatment market.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CPIX Stock
What is Cumberland Pharmaceuticals Inc.'s (CPIX) stock forecast for 2026?
Analyst forecasts for Cumberland Pharmaceuticals Inc. (CPIX) are not currently available. The stock is trading at $3.04.
Is CPIX stock a good investment in 2026?
According to current analyst ratings, CPIX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CPIX stock?
Price predictions from Wall Street analysts for CPIX are not currently available. The stock is trading at $3.04.
What is Cumberland Pharmaceuticals Inc.'s business model?
Cumberland Pharmaceuticals generates revenue by developing and commercializing niche-market prescription products that cater to specific medical needs in hospital acute care, gastroenterology, and oncology. The company employs a direct salesforce and partners with healthcare providers and distributors to maximize product availability across the U.S.
What is the highest forecasted price for CPIX Cumberland Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CPIX are not currently available. The stock is trading at $3.04.
What is the lowest forecasted price for CPIX Cumberland Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CPIX are not currently available. The stock is trading at $3.04.
What is the overall CPIX consensus from analysts for Cumberland Pharmaceuticals Inc.?
The overall analyst consensus for CPIX is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CPIX stock price projections?
Stock price projections, including those for Cumberland Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 2:32 AM UTC